DISCOVER. INVEST. CURE.

89bio, Inc. is a clinical-stage biopharmaceutical company focused on NASH and other liver and metabolic disorders. Its lead product candidate, BIO89-100, is a novel long-acting FGF21 analogue. They are based in California and Israel. 89bio, Inc. recently closed a $60M series A financing.

AADI is a clinical phase company with a registration trial in malignant PEComa (an orphan aggressive sarcoma) with NDA filing targeted in 2019. AADI’s drug ABI-009 is being developed in diseases driven by mTOR activations in oncology, cardiovascular and CNS including colorectal cancer, pulmonary hypertension, refractory epilepsy and mitochondrial disease.

Unique technology platforms to develop new kinds of therapeutic antibodies. Great in-house therapeutic antibody pipeline for difficult to treat cancer and CNS. Broad partners and clients network. They are raising Series A funding to move on their leading programs to clinical stage.

Integrated therapeutic for Multiple Sclerosis delivering best-in-class efficacy while setting new standards for safety and value-based cost efficiency. The Company's development pathway is significantly de-risked by repositioning a well characterized biologic for a new indication, creating a unique competitive entry in a disease with continuing high levels of unmet need.

Capital raise to support four Phase II programs (5-15M).

Clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells.

APT’s approach has been developed explicitly to address past limitations of phage, and has resulted in a rapidly deployable, cost effective treatment for otherwise recalcitrant infections. APT acquired exclusive rights to PhageBank and related technology from the US Biological Defense Research Directorate after multiple successful initial in-human uses.

APT’s approach has been developed explicitly to address past limitations of phage, and has resulted in a rapidly deployable, cost effective treatment for otherwise recalcitrant infections. APT acquired exclusive rights to PhageBank and related technology from the US Biological Defense Research Directorate after multiple successful initial in-human uses.

AdCure Bio is a pre-clinical stage cancer ViroTherapy company. Its lead drug candidate AVID-317 passed pre-clinical non-GLP toxicology tests and demonstrated efficacy in animal models of lung cancer. Next milestone includes AVID-317 GMP production, IND-enabling tests, and completion of Phase-I clinical trial. AdCure has a pipeline of assets in development.

Aegle Therapeutics is a first in class, Phase I/IIa-ready, biotechnology company isolating extracellular vesicles secreted by allogeneic bone marrow derived mesenchymal stem cells (“BM-MSCs”) to treat severe dermatological conditions. Aegle’s platform technology is initially being developed to treat epidermolysis bullosa, a rare pediatric skin blistering disorder, and burns.

Affigen is building a first-in-class platform for tumor-identifying mAb and CAR therapies in both hematologic and solid cancers. Its lead tumor-identifying mAb program in incurable B-cell malignancies is expected to enter the clinic in 1H 2020, followed closely by additional CAR and mAb programs in hematologic and solid tumors.

AgeX Therapeutics is one of the leading companies targeting what may be the largest unmet need in all of medicine: age-related degenerative diseases. This market is primed to grow dramatically in coming years with the baby boomer "age wave" and parallel trends in other developed economies.

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Its product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.

BDA12: is a molecular switch, which turns amide local anesthetics into triggers that release endogenous opiates for long lasting pain control with full return of sensation. ZAPP: has a unique antimicrobial action, which kills most resistant bacteria, lipid-coated viruses and fungi with extraordinary healing capacity and very limited scarring.

AIVITA Biomedical is a next-generation immunotherapy company with two phase 2 programs in oncology and a pivotal trial about to initiate in Japan. They have solid data in efficacy and mechanism of action to support their platform in multiple solid tumors and an efficient, low-cost manufacturing process.

Akadeum is a market-ready sample preparation company. Building on two issued patents that utilize microbubbles, the company has seven products ready for commercialization in the $687M cell separation research market. The company is also in the process of forming partnerships in the diagnostic and cell therapy markets.

Aktivax has a $55M Government contract to advance next generation auto-injector emergency treatments to GMP manufacturing capability Q4 2019 and then to FDA approval and government procurement revenue. They will move into high value non-government markets of >$2B including, naloxone/nalmefene, ephinephrine, and glucagon; development to begin in 2019.

Allevi allows scientists to study the body outside the body. Constructs within hydrogels and microfluidic systems allow for personalized disease diagnostics to test efficacy or safety and efficacy simultaneously. The approach allows it to pattern multiple cell types in certain pattern or add vascularity to achieve systems biology responses unseen.

Alpha Tau Medical is a clinical-stage company focused on high-precision alpha-emitters radiotherapy for all types of solid tumors. Feasibility clinical trials are currently commenced at over 50 leading cancer centers worldwide for various indications, with first promising results in SCC, including a preliminary finding of systemic immune response.

AGT is a gene and cell therapy company on the eve of the clinic with a cure for HIV (estimated first in-patient: mid-2019). In parallel AGT is developing a novel immuno-oncology approach demonstrating 85% complete remission in mouse models (complete clearance of the tumor).

Amorsa's NMDA receptor modulators are highly differentiated oral therapies targeting multiple CNS disorders. The Company has substantially mitigated the development risk, secured a strong IP estate and has the core team in place to execute on the milestones.

Anaeropharma Science is a clinical stage company aiming solid cancers. Its leading product is under Phase 1 clinical trials in the U.S. for solid cancers. There are also multiple preclinical projects in development for solid cancers.

ANGLE is world leading liquid biopsy company with a sample to answer solution. ANGLE's proprietary platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for low cost, highly multiplexed analysis of nucleic acids and proteins.

Anima Biotech is advancing Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against many diseases. With novel biology that monitors the translation of proteins and proprietary cloud-based software, they identify drug candidates that modulate a target protein’s production. They develop a pipeline across therapeutic areas and partner with Pharma for their targets including their $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Their approach was further validated with 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.

-First-in-class, first-in-disease, late stage products -World-class team with extensive proven track record -Newly elected Fierce 15 winner

The company has two first-in-class nicotine blockers. The lead candidate, ATI-1013, a human anti-nicotine mAb, has entered preclinical development. FDA has designated ATI-1013 an Orphan Drug in Buerger's disease, a vascular ischemic disease in which nicotine plays the most important role in initiation and progression of the disease.

Multiple near term catalysts with potential data for APTO-253 P1b clinical trial interim data in Q1/2019 and the initiation of separate parallel P1 trials in relapse/refractory AML and certain B cell malignancies in Q1/2018.

Arch is transforming the landscape of advanced interventional wound care. The company's lead product AC5(TM) is currently in clinical development in both the United States and Europe and is expected to be marketed in the second half of 2019.

Aridis (Nasdaq: ARDS) is a late-stage biopharmaceutical company focused on discovering and developing targeted immunotherapies using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. The Company has three candidates in active clinical development, with three clinical data readouts in 2019.

Arivale's program uses innovative science, genetic, microbiome and clinical data, and tailored coaching to deliver personalized wellness solutions. Participants opt in and consent to having their data used for bio-pharmaceutical research. Over the past 12 months, Arivale scientists and external collaborators have completed several discovery projects, with very promising results.

Company entered clinical development stage Q4 2018. Lead project ATR-002 will have clinical PoC (Phase 2 challenge) in Q4 2020. Phase 2b in Q3 2022. Pipeline Project hantavirus enters clinical development in 2020. Pipeline RSV in COPD exacerbation enters clinical development in 2021. Total Investment US$ 36 Mn to 2022.

aTyr's ATYR1923 is a potential therapeutic for patients with ILD. ATYR1923 is a fusion protein comprised of the immuno-modulatory domain of HARS fused to the FC region of a human antibody. ATYR1923's Phase 1b/2a targets pulmonary sarcoidosis. aTyr is pursuing partnerships and further funding to expand into other ILD indications.

Aural Analytics represents the most advanced speech and cognitive biomarker company in the world based on its data, clinical validation, partnerships and unique technology approach. The company has a clear path to reaching wide adoption, FDA approval beginning with motor diseases, and shortly after will also achieve cognitive disease approvals.

Auransa’s technology platform provides a comprehensive and innovative approach to drug discovery and development, designed to overcome the challenge of heterogeneity – a primary cause of clinical trial failures, as well as differential treatment response among patients once a drug reaches the commercial market.

Avectas has developed a disruptive non-viral delivery technology to enable the manufacture of next-generation cell therapies. They believe their technology will reduce manufacturing cost and time and the resulting engineered cells will be highly functional and perform better in the body.

AXIM is providing a full-package solution to the pharmaceutical cannabinoid space. AXIM boasts a robust IP portfolio, three-phase clinical development program prioritized by time-to-market designed to enable AXIM to self-fund further phases, and proprietary trans-mucosal, controlled release delivery system superior to others currently on the market.

Axsome Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines for the management of central nervous system (CNS) disorders. By focusing on this therapeutic area, they are addressing significant and growing markets where current treatment options are limited or inadequate.

AyuVis is a pre-clinical stage company focused on immunological disorders. Its lead candidate is currently in preclinical-IND enabling for the treatment of Bronchopulmonary dysplasia, a pediatric orphan indication of severe lung injury. It also has two preclinical assets for Pseudomonas aeruginosa lung and skin infection and systemic inflammatory response syndrome.

Azitra has established a robust product pipeline addressing cosmetic use of the microbiome as well as three Live Biotherapeutic Products based on the delivery of therapeutic proteins to the skin. The Company's products target: eczema, psoriasis and the orphan indication Netherton. Azitra will be entering human testing this year.

The company has completed a Phase 2a study with chronic pancreatitis patients and is initiating a Phase 2b study with cystic fibrosis patients of its MS1819 recombinant lipase for the treatment of exocrine pancreatic insufficiency.

Bell is entering the commercialization stage for The Magnelle platform, a unique and simple method of delivering ex vivo gene editing machinery and / or cell reporters into stem and primary cells. The platform can be instrumental in immuno-oncology, hematopoietic gene disorders, infectious diseases, and progressive dystrophia diseases therapeutic development.

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for advanced and aggressive cancers. Bemcentinib is a potentially first-in-class selective AXL inhibitor in a broad PhII clinical programme in solid and heamatological tumours as monotherapy and in combination.

The xB³ platform technology is a non-invasive, multi-modal solution to the problem of transporting complex therapeutic molecules across the BBB. The xB³ platform consistently outperforms competitive technology in terms of payload flexibility, efficiency of delivery and payload amount (% in brain).

Biois focused on diagnostics and targeted drug businesses. Its lead diagnostic product is currently in commercial stage with Lab Developed Test Service in EU and US. For the Aptamer based drug carrier, they finished animal model in-house test and proved Aptamer Drug Carrier reduces side effect and targeting tumor cells.

BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

Biolojic has validated its Machine Learning discovery platform for: 1. DualBodies (hmAbs that bind two unrelated targets maintaining natural IgG symmetrical format) 2. Creating mAbs that bind difficult targets (e.g. ion channels) 3. Selectively modifying mAb properties (e.g. specificity) Seeking investments supporting development of internal programs and technological platform enhancement.

BioMarker Strategies, LLC is a privately held molecular diagnostics company with patented core technologies that enable more accurate, individualized predictions of response to targeted treatments for solid tumor cancers. With funding, they believe their technologies can be expanded dramatically to multiple solid tumors - and to other diseases as well.

Bionetix is a pre-clinical stage company focused on the development of novel small molecule drugs targeting eye diseases and oncology. The lead product is a novel topical glaucoma treatment and a novel oral treatment for AML. Bionetix is planning to begin Phase I clinical trials in 2019.

The company is open to new investment to support moving BN201 into PoC Phase 2 study.

The NGAL Test™ detects AKI far earlier than other tests on the market. AKI, a well-known complication resulting from injury to the kidney. NGAL enables to plan a care pathway more quickly and effectively, reducing the risk of renal failure and mortality. NGAL is currently under review by the FDA.

BioXcel Therapeutics' leads assets are in clinical development with the potential to expand the number of indications and advance rapidly into registration trials. These efforts would require additional investments.

BlueWillow is seeking to raise $5M+ in 2019 to support efforts to partner and launch a novel topical nano-scale treatment for preventing and treating infections in wounds, burns and skin, while it continues to advance several intranasal vaccines into advanced preclinical and clinical studies with NIH funding.

NurOwn induces the differentiation of purified and expanded bone marrow derived mesenchymal stem cells (MSC) into cells capable of releasing high levels of multiple neurotrophic factors for neuroprotection, while maintaining the intrinsic immunomodulatory effects of MSC. The drug has an encouraging phase 2 safety profile in ALS.

Bridge is seeking investment of $16M. The first tranche of $1M will take our exciting cellular results and prove that the peptide compounds work in explanted human inflammatory tissue. The following $15M investment will acquire the peptides and drive the lead compound thru full pre-clinical development thru to IND approval.

Canalis Pharmaceuticals is a start-up biotech company engaged in drug discovery and development of rare cannabinoids. Using synthetic biology and medicinal chemistry they have one-of-a-kind chemical libraries of rare natural cannabinoids, prodrugs and semi-synthetic derivatives. Its first product, a THC inhaler for CINV, is in preclinical development.

Based upon the FDA review of their successful Ph 2 efficacy data, the FDA has agreed that they can initiate two pivotal Ph 3 trials leading to a BLA submission. The company is planning a $25M IPO, with a X-over round, to fund Ph 3.

CASI Pharmaceuticals (NASDAQ: CASI)/~$300mm MC) US headquartered biopharmaceutical company; Beijing-based R&D operations o In-licensed products from Spectrum Pharma o EVOMELA®: FDA-approved; CFDA priority review o ZEVALIN® & MARQIBO®: FDA-approved, CFDA review in progress o Acquired 25 FDA-approved ANDAS from Sandoz o Acquired an FDA-approved ANDA from Laurus Labs

Ceapro is a biotechnology company involved in the development and commercialization of “active ingredients” derived from oats and other renewable plant resources. Ceapro utilizes its proprietary plant extraction-based manufacturing process to supply ingredients to well-known personal care and cosmetic industries and is developing beta glucan and avenanthramides in biopharmaceuticals.

HybriCure®, a precision personalized autologous advanced cell-based medical product, now available for treating prostate cancer. Proposition: Tech Transfer/Licence-Out SmartCure®, Current studies provide proof-of-concept (POC). Proposition: Fund raising to reach first-in-human study stage (investment).

Cellectar (NASDAQ:CLRB) is developing PDCs designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. They believe this platform, based on their proprietary small-molecule cancer targeting vehicle, has the potential to improve the therapeutic window of diverse oncologic payloads.

Virtually every AML therapy causes prolonged neutropenia and there is no effective therapy to prevent infections while AML patients are neutropenic. In Phase 2, romyelocel-L showed superiority over G-CSF, and the more AML treatments expand, the more need there is for romyelocel-L. AML market is a $1 billion opportunity.

CellMax Life has developed the first and only blood test for colon cancer prevention with high accuracy demonstrated in a prospective clinical study for the detection of pre-cancer. Market opportunity in the US alone is 125 million Americans >45 years old and annual TAM is $20B.

Cerebrum's SAAS applications provide a 4X efficiency gain to the pathologist and lab tech’s daily work output, optimizing the most expensive part of labs. We have an on-going contract with a top-5 Biotech company to help create their genomics workflow.

A fast to market, low capital requirements, and reduced risk biotech. Nasdaq/TSX IPO planned for 2H-2019. Four patches in development with two patches to be ready to enter Phase-3 trials Q3-2019. Reformulated products designed to differentiate with clear on-label superiority in a market with significant unmet medical needs.

• Four LOIs for $730K revenue upon launch (includes oncology practice, urgent care chain, and a large health system serving 2M people) • Three core provisional patents filed • Prototype complete with blood results • Part of IndieBio accelerator and Plug&Play Health • 30% hard commits towards $3M Seed round

Biopharmaceutical company leveraging its drug delivery platform technology that enables once-daily tablets of multi-dose therapies. Cingulate’s lead products are first-line stimulant medications for the treatment of ADHD utilizing the accelerated 505(b)(2) regulatory pathway. They have completed a PoC trial and will commence Phase 1/2a trials in the coming months.

Over $23 million was invested privately by the founders and insiders and $19 million by the public. Citius Pharmaceuticals has a status report on Mino-Lok® Phase 3 trial (>12 sites) and an international study at MD Anderson sister Institutions supported Mino-Lok® Phase 2b results: 95% efficacy in salvaging infected catheters.

Concarlo has robust proof of concept data: their therapeutic causes dramatic tumor regression and better overall survival benefit in vivo compared to standard of care (Palbociclib). Concarlo has multiple partnering opportunities and is addressing resistant breast cancers. Preclinical work initiated in 2019 and clinical trials projected for 2020.

A clinical-stage company focused on autoimmune disease and inflammation. Its lead product is CBP-307 currently in two Phase 2 clinical trials for ulcerative colitis and Crohn’s disease. Its second product is CBP-201 currently in a phase 1 study. The company also has three other drug candidates currently in preclinical development.

Context is a clinical stage biopharmaceutical company focused on hormone-driven cancers. The company's lead program is Apristor, an oral progesterone antagonist that is in Phase 2 development in breast cancer and rare, underserved gynecological cancers. Additionally, the company has two preclinical programs.

ContraFect is a clinical-stage biotechnology company with a first-in-class lysin candidate, exebacase (CF-301), completing a Phase 2 superiority trial for the potential treatment of Staph aureus bacteremia and endocarditis. The company's products are differentiated not only by structural class, but also by the objective to be superior to existing treatments.

Crescendo is a late preclinical stage company with several preclinical IO assets and a development focus on CB307, its targeted Humabody T-Cell Enhancer. Multi-functional Humabodies deliver novel biology and superior bio-distribution. Crescendo has a strategic partnership with Takeda Pharma in the areas of Humabody Drug Conjugates and novel IO approaches.

• Proven management team and board of directors • Intellectual property portfolio • CVSI-007 targets growing multi-billion dollar market • Over 50 SKUs – products in 2, 093 stores as of September 30, 2018 • No. 1 selling hemp CBD supplements • Total assets of $31M as of September 30, 2018

Cyclacel is a pioneer company in the field of cell cycle biology with a vision to improve patient healthcare by translating cancer biology into medicines. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates.

Cypralis is developing a pipeline of novel cyclophilin inhibitors for liver fibrosis, neurology and other indications. Lead programs will enter the clinic in 2019 and are targeting acute indications with clinical PoC readouts during 2020/21. Seeking pharma collaborations and/or Series A financing of US15-20M in H1 2019.

CytoDyn is developing leronlimab (PRO 140), a novel humanized monoclonal antibody targeting the CCR5 receptor. The Company plans to file a BLA in 1Q19 as a combination therapy following a successful Phase 3 trial and recently received FDA approval to initiate a clinical trial in metastatic triple-negative breast cancer.

The Company is looking to raise $30-50M to fund an upcoming Phase II trial.

CytoSorbents Corporation (NASDAQ: CTSO) is a critical care immunotherapy company commercializing its CytoSorb blood purification technology in 53 countries worldwide to treat deadly inflammation in life-threatening conditions in the ICU and cardiac surgery. $19.1M trailing 12-month sales, 72% gross margins, 4 major partners: Fresenius, Terumo, Biocon and Dr. Reddys.

DCprime's lead product is a cell-based cancer vaccine which is currently being tested in an international PhIIa trial in AML. Preclinical evidence supports the applicability of the same product in multiple myeloma and in solid tumours. They aim to raise additional funds to launch 2 new clinical trials in 2019.

The Company is well funded through to 2020 and has a lead program completing a Phase 2b in US in 2019 in prevention of post-surgical infection. The Company owns its own IP and has one regional deal for China rights with China Medical Systems who are also an investor.

DTx is a preclinical stage company that has developed technology to enable the activity of siRNA medicines beyond the liver. The proceeds of its series A will be utilized to optimize the technology for systemic applications and, in parallel, develop and advance candidates into IND-enabling studies for eye and CNS.

Potential game changing industry proven C1 Gene Expression Platform - with the potential to disrupt bio-manufacturing *Cash & Liquid Investments ~$42.8 MIL (as of 9/30/18) * Repurchased Shares of $ 21.8 MIL since February 2017 * Filed an initial Form 10 with the SEC company in November 2018

EarlyDiagnostics developed an accurate and affordable blood test to detect and locate multiple cancer types. The reagents/sequencing/computing cost of the test altogether is less than $100.

EMB-001 results to date have generated significant interest from the pharma industry. Embera has ongoing discussions with 24 pharma companies interested licensing or acquiring EMB-001 with positive Phase 2 data. Its current Series B financing will fund Phase 2 studies in its lead indications to a potential exit or IPO.

EHP initiated its first Phase I clinical trial on EHP-101 in Q3 2018 for the treatment of multiple sclerosis and scleroderma. We have received Orphan Drug Designation from the FDA and EMA for our scleroderma indication. Phase II is planned for late 2019, along with a NASDAQ IPO.

Enochian Biosciences has raised $19M to advance to proof-of-concept in human gene modified cell therapy in HIV and immuno-oncology. The company has been listed for 3 years on OTCQB (ENOB) and has applied to an uplisting to Nasdaq.

A clinical stage biopharmaceutical company with an innovative formulation technology that enables the oral delivery of peptides and small molecules with poor solubility/permeability. Two internally sponsored development programs in the clinic: oral leuprolide for endometriosis and an oral tobramycin for uncomplicated UTI (Phase 1 safety complete).

ENYO Pharma is a privately held clinical stage Biotech with a unique drug discovery engine inspired by viruses. The company will start two Phase 2 with its lead compound in HBV (first-in-class) and in NASH. Another compound (new mitochondrial target) will enter IND enabling studies in 2019 (metabolic diseases).

Late-stage clinical company developing EC-18 for oral mucositic and chemotherapy-induced neutropenia. Market cap USD 800+ and growing quickly since its IPO in Korea in Feb 2018. Seeking partnership deals - both outlicensing and inlicensing.

EOC is a clinical stage Oncology focused organization. It has 4 clinical programs running with its lead product candidate moving into registration studies in China in 2018 (HDACi for ER+ breast cancer). Expect to follow to the clinic in 2019 with its first-in-class Lag-3 fusion protein program.

EpiVax Oncology has completed its pre-IND meeting in July 2018 and is preparing to enter a Phase 1b clinical trial in 2019.

eTheRNA immunotherapies is a clinical stage developer of mRNA-based immunotherapies for cancer, focusing on therapies that prepare and activate the immune system by programming dentritic cells (DC) with synthetic mRNA.

Eutilex is expanding to the US the 4-1BB autologous adoptive T cell therapy that proved safe without ADR in all patients and compelling efficacy also in solid cancers. Additionally, the first-in-class Treg converting antibody EU102 with strong single-agent potential and the best-in-class 4-1BB modulating antibody EU101.

Evolution is targeting a high value, high need market using a low-cost approach to rapid generation of commercial revenue. This work is based around its unique intellectual property and expertise in bringing biological controls into the biomedical sector. Investment is sought to support its operations towards its planned IPO.

Exicure believes SNA technology has the potential to target diseases not addressed with other nucleic acid therapeutics. It has two clinical candidates: AST-008 for immuno-oncology, beginning a Phase 1b/2 trial in December of 2018 and XCUR 17 for inflammatory disorders, completing a Phase 1 clinical trial in December of 2018.

Fibriant is a pre-clinical stage company focused on recombinant production of specific fibrinogen variants. Its lead product is currently in pre-clinical development for the treatment and/or prevention of (multi resistant) staphylococcus aureus infections.

FLAG's current pipeline consists of four targeted molecules on two novel platforms. FLAG’s first two assets are funded through IND submission. FLAG's team has held senior level positions at companies including BioMarin, Patheon, DPT Labs and Ultragenyx where they gained extensive experience developing assets from R&D to licensing and/or commercialization.

Family owned advanced wound/skin care company Patents in key global markets No external capital: R&D and growth funded by positive cash flow POC: own sales teams established leading market positions (BE, NL, UK) Growth: 3 year sales CARG +20% Requires entrepreneurial investor providing operational support est. USA / Japan

Addressing key areas of concern in Cell and Gene Therapy; manufacturing costs, product quality, scalability, and simplification. • Enabling technology to an estimated $20B (2023) market • Commercial product available Q1 2019, ongoing accelerated development program • High profile co-development partnership in place, several in discussion

Flow Pharma is a pre-clinical biotechnology company in the immuno-oncology space beginning Phase I/II clinical trials in 2019 to support an orphan drug indication for advanced cervical cancer. The Company is also starting a neoantigen screening clinical study for a breast cancer indication in 2019.

Fulcrum is focused on small molecule therapeutics for diseases of gene misregulation. The company is creating therapeutics for a range of genetic disorders including: FSHD, Sickle Cell Disease, as well as other neuromuscular diseases. Fulcrum plans to file its first IND in FSHD in 1H2019.

G+FLAS Life Sciences developed proprietary CRISPR/Cas genome editing technologies. G+FLAS seeks partners to license the technologies for their cell or gene therapy applications as well as crop trait development. G+FLAS produces plant-made pharmaceuticals. With company's CRISPR technologies, the glycosyltransferase genes of host plants were precisely engineered to produce glyco-optimized biobetters.

Geneius expands natural T Cells to overlooked tumor-specific antigens to optimize homing, killing, spreading, and memory for durable responses. Its T Cell therapy entering company-sponsored clinical trials in 2019 demonstrated lower toxicity/comparable efficacy to CAR-T therapies, in academic clinical trials, at 10% of the cost. IPO anticipated in early 2021.

GeneTether is an early stage company developing high efficiency gene editing technologies for human therapeutics. GeneTether plans to initiate preclinical development Q1 2020 for two human therapies (not disclosed). Agbio and research reagent applications will be partnered/out licensed.

Genevant aims to deliver innovative and meaningful therapies that improve the lives of people through a diverse pipeline of nucleic acid-based medicines. By pursuing a multiple modality “pan-RNA” approach to drug discovery and development, Genevant is well-positioned to select and advance the best therapeutic approach for each disease area.

Genexine is a clinical stage company focused on biologics based on two platform technologies. Genexine’s lead product for growth hormone deficiency is currently preparing IND submission for global Ph3. Genexine is also developing Fc-based IL-7, as an IO agent and has four more assets in different clinical stages.

Genome & Company develops novel therapeutics in Oncology. - Immune oncology (GEN-731): Microbiomes which have synergistic effect with immune oncology drugs, such as Anti-PD-(L)1 inhibitors (Preclinical stage) - Immune oncology(GENA 001~010): Novel-targeted immune checkpoint inhibitors (Antibody) which have the potential to apply for Anti-PD-(L)1 refractory/resistant patients (Preclinical stage)

Genosco has developed three highly selective kinase inhibitors in clinical stage. Phase2 EGFR inhibitor for non-small cell lung cancer (NSCLC) entered licensing agreement with Janssen (total deal size: $1.255B). Phase2 SYK inhibitor for rheumatoid arthritis (RA) & immune thrombocytopenia (ITP). Phase1 FLT3/AXL inhibitor for acute myeloid leukemia (AML).

Genprex™ is a clinical stage gene therapy company developing a new approach to treating cancer, based on its novel proprietary technology platform, including its initial product candidate - Oncoprex™ immunogene therapy undergoing phase 1 and 2 trials in combination with different NSCLC therapies.

1. To find out investors and partners for further development and commercialization of Neu2000 for the treatment of acute stroke and cardiac arrest patients. 2. To find out investors and partners for further development and commercialization of AAD-2004 for the treatment of neurodegenerative diseases and pet cognitive dysfunction syndrome.

This company is a clinical stage company focused on NSCLC and cardiometabolic disease. It's lead compound Antroquinonol is currently in Phase 2a for the treatment of pancreatic cancer, atopic dermatitis and chronic hepatitis B.

GreenBone Ortho is a clinical stage company focused on bone reconstruction and regeneration. EU class III Medical Device, FDA 510(k). Two EU clinical studies in patients with non-loaded and load-bearing bone defect (over 3 cm) to be completed by end 2020. Other applications under preclinical development.

GT Biopharma is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology products based off proprietary TriKE, TetraKE and bi-specific (ADC) technology platforms. Phase 2b data from lead program, GTB-1550 expected 1Q 2019. Recent IND cleared to initiate a first-in-human Phase 1 study with GTB-3550.

Haisco is a public listed company focusing on R & D of therapeutic new drugs. It grows its portfolio by seeking out innovation opportunity. It is looking for in-licensing opportunities for China Market and interested in meeting in the fields of pain management, perioperative medication, diabetic complications, and inhalation drug.

Regenerative medicine is an emerging field that will have a profound impact on human lifespan and health span. By successfully leveraging the Japanese regulatory framework, a partnership-building, and expert sourcing and development of promising technologies, Healios is dedicated to making the "life Explosion" it envisages a reality in our lifetimes.

T-cell activating platform (TCAP) produces allogeneic, off-the-shelf therapies designed to activate the immune system to turn immunologically “cold” tumors “hot.” Heat's therapies are designed to be administered with checkpoint inhibitors and other immuno-modulators to enhance immune response.

HighTide's lead drug candidate, HTD1801, is in Phase II for multiple liver diseases: PSC, NAFLD/NASH, and hypercholesterolemia. HTD4010 has completed Phase I and is poised for Phase II in acute pancreatitis. HTD2802 is a drug candidate for IBD. Multiple value-driving data results are expected in 2019.

Ibex is developing AI-driven algorithms in pathology, leading to rapid, accurate, and objective cancer diagnosis, bringing new promise to the fight against cancer with tremendous upside to patients and sizable savings to the health system, with already proven clinical results as the first instance of AI diagnosing cancer.

IGEM is a UK Immuno-Oncology company developing novel IgE antibodies to treat cancer. Unlike IgG, IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with key features that make it ideal for the treatment of solid tumours. IGEM-F is currently in a Phase I/2a trial to treat ovarian cancer.

IGF Oncology is a clinical stage company with its lead drug IGF-MTX in a Phase 2 clinical trial at Mayo Clinic in Myelodysplastic Syndrome (MDS), a fatal bone marrow cancer with no good approved drugs, and its drug was effective in both of the two patients treated to date.

illumiSonics is a clinical stage company with a breakthrough technology for medical imaging applications in R&D, pathology, endoscopy, surgery and ophthalmology. Five peer-reviewed papers describe technology and applications in top rated optics journals. Industry interest is strong and likely to lead to partnerships and/or eventual acquisition.

ImaginAb is seeking to raise venture capital funding to support two Phase 2 clinical trials, centralize manufacturing at a specialist CDMO, and seed investigator-sponsored trials. The company projects to become cash flow positive in 2019.

Immunic’s three development programs include orally available, small molecule inhibitors of DHODH (IMU-838 program), an inverse agonist of RORγt (IMU-935 program) and IMU-856 (undisclosed novel target) relevant to diseases such as ulcerative colitis, Crohn’s disease and psoriasis. The final aim is to develop these oral drug candidates to clinical proof-of-concept.

Immunicum is advancing a novel immune-priming cancer treatment against a range of solid tumors with its lead program ilixadencel, an off-the-shelf allogeneic cell-based therapy that has demonstrated a potential to become a backbone component of immuno-oncology combination treatments. The company is listed on the Nasdaq Stockholm small cap.

ImmunoMet is a VC funded biotech utilizing cellular metabolism to develop novel anti-tumor and immune metabolism therapies. ImmunoMet is a spin-off from HanAll, a mid-sized Korean pharma company, headquartered in Houston JLABs near MD Anderson and founded in 2015. Its lead molecule is an OXPHOS inhibitor currently in Phase I.

Immunovative Therapies is seeking investment to recruit an executive management team and advance its lead product, StimVax, to Phase IIb in metastatic colorectal cancer in the USA and in advanced/metastatic liver cancer in SE Asia . It will also complete the development of its prototype automated, scalable manufacturing systems.

The ISP™ platform is an alternative to viral-based gene therapies, offers broad utility to produce virtually any biologic drug entity, and has the potential to disrupt standard of care for several cardiovascular, autoimmune, neurodegenerative, and rare orphan diseases that require frequent recombinant ERT or protein replacement therapy.

Imugene's vision is to help transform and improve the treatment of cancer and the lives of patients . Imugene is well funded and resourced to deliver on its commercial and clinical milestones. Imugene's goal is to ensure Imugene and its shareholders are at the forefront of this growing global market.

InCarda's lead asset, InRhythm, addresses a significant unmet need for patients with acute episode of atrial fibrillation. If approved, it will be the only treatment on the market that will allow patients experiencing an episode to convert in minutes, no matter where they are, with or without a physician.

Novel immunotherapies have generated tremendous interest by investors, but to date, CAR-Ts have demonstrated poor responses in solid tumor cancers. By uniquely combining with standard-of-care doses of chemotherapy, Incysus seeks to modulate the tumor microenvironment to reduce immune suppression while driving increased tumor immunogenicity.

Indi Molecular is a preclinical stage company that's focused on Theranostic oncology targets. The company is capable of simultaneously pursuing several different oncology targets based upon its high throughput real-time synthetic peptide chemistry platform. The B round will fund Phase 1/2 oncology clinical development commencing first with molecular imaging.

Best in class liquid biopsy technology.

InMed is developing novel, non-THC, topically applied cannabinoid-based treatments of diseases with high unmet medical needs. This potentially industry-disruptive cannabinoid manufacturing process may offer several advantages over traditional methods, such as plant extraction and chemical synthesis.

Inovio is a clinical stage company focused on cancer and infectious diseases. Its lead product VGX-3100 is currently in Phase 3 trials for the treatment of HPV-related cervical dysplasia (precancer). Another product INO-5401 is in Phase 2 trials for the treatment of glioblastoma and bladder cancer.

The company is launching two neurological products in Qtr4 2018 and would like to seek Seed/Series A funding to help accelerate its growth, run two Bioequivalence studies and apply for marketing approval in more countries. The company is currently in negotiations to bring in a further three products.

Invivoscribe is a leader in standardized molecular testing in hematology-oncology. Its Streamlined CDx™ approach has proven successful in helping pharmaceutical companies accelerate FDA and PMDA approvals. Invivoscribe developed CDx assays for Novartis, Astellas and is currently engaged in CDx development for a number of drug candidates from leading pharmaceutical companies.

Iota is a clinical stage life sciences company advancing the development and validation of its transformative 'Neural Dust' bioelectronic monitoring and neuromodulation (i.e., neurostimulation) technology platform. Today's healthcare system is aggressively interested in continuous battery-free internal physiological monitoring. Iota is building such an ecosystem, and with significant valuation.

The company is a preclinical stage company focused on CNS disorders. It’s lead product has completed the GLP preclinical phase for the treatment of CIAS and Parkinson’s disease. Clinical Phase I study will start in 2Q2019. It also has a preclinical asset for a disease-modifying treatment of epilepsy or epileptogenesis.

Only compound in TBI to show significant improvement vs placebo in rat and pig models of TBI with endpoints of biochemical assays of brain injury, sensorimotor, memory, learning, cognition, and sleep/rest cycle. Multimodal therapy activates PI3k/Akt; up-regulates mitochondrial energetics; modulates calcium overload; suppresses free radical generation; superior to single-mode candidates.

ISLA Pharmaceuticals is developing its lead compound for the treatment or prevention of dengue, an orphan and Priority Review Voucher (PRV) eligible disease, with significant unmet need. ISLA will initiate a Phase 2 study in dengue patients in 2019 with a novel and rapid clinical strategy.

Small cap biopharma with an FDA-approved drug and an advanced pipeline of potential follow-on indications and therapies with multiple possible value-enumerating catalysts over the coming quarters.

Each year in the US, surfactant insufficiency precipitates respiratory distress in 140, 000 premature babies and 60, 000 patients with acute lung injury. Adoption of non-invasive surfactant aerosol therapy using KAER’s patented SUPRAER platform technology can prevent high complication and mortality rates while providing revenues of $1B.

NT-814 has the potential to be a true breakthrough with blockbuster potential. It has the potential to become a viable alternative to hormone therapy to treat millions of women globally who suffer debilitating symptoms on a daily basis.

Kazia Therapeutics has a high-quality, mid-clinical-stage pipeline, with four data read-outs anticipated in 2019. In addition, there are several collaborative studies underway with the lead asset, GDC-0084, that could significantly extend its use beyond the lead indication of glioblastoma.

Kedalion is a clinical-stage company in the ophthalmology space, aiming to transform topical drug delivery with its proprietary AcuStream platform. The worldwide market for topical ocular therapies is greater than $17B and every therapeutic area is ripe for innovation to improve patients' experiences with delivery, safety, adherence and compliance.

This company is a clinical stage company bringing a lead biologic that has been found to be safe and effective against a previously untreatable known chronic oral bacteria in the mouth that is the well known cause of systemic and local cardiovascular disease and stroke.

Kiadis is a clinical stage biopharmaceutical company. Lead product candidate, ATIR101, has been filed for approval in EU based on Phase 2 data, as an adjunct to haploidentical hematopoietic stem-cell transplantations for adult blood cancers. Phase 3 trial ongoing against the Post-Transplant Cyclophosphamide protocol.

Kleo Pharmaceuticals is an immuno-oncology company pioneering new classes of small molecules and synthetic peptides designed to emulate or enhance biologics. The company is advancing several drug candidates and collaborating with partners to develop Antibody Recruiting Molecules (ARMs), Synthetic Antibody Mimics (SyAMs) and Monoclonal Antibody Therapeutic Enhancers (MATEs).

KromaTiD’s products and services are today helping the leading gene editing companies advance therapies to market and reduce the risk to patients. To meet the full current demand and revenue opportunities in 2019 and beyond, KromaTiD must develop and launch scalable, high-throughput versions of its products.

Based on the FDA acceptance of its 2 INDs and the completion of their Phase 1 trial of BT-11, they are planning to initiate its Phase 2 study in early 2019. To fund Landos’ clinical development program, they seek to raise a $60M Series B round of financing.

Leading Biosciences' lead candidate, LB1148, has the potential to become a best-in-class oral drug to improve return of GI function and shorten patients’ length of stay (LOS) in the hospital following major surgery. Recent positive interim data from its ongoing Phase 2 trial demonstrated a decrease in LOS of 3.2days.

Matinas is a clinical-stage biopharmaceutical company focused on the development of MAT9001, a prescription-only omega-3 fatty acid comprising EPA and DPA for the treatment and prevention of cardiovascular and metabolic disease, and enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal platform technology.

MatriSys Bio is a clinical stage Skin Microbiome Company focused on dermatology and skin care. Its NIH sponsored Phase 2A in atopic dermatitis clinical trial began Sept 2017; two sites in US. Current Rx portfolio includes two advanced assets: MSB-01 (Phase IIa for atopic dermatitis) and MSB-03 (Phase II, Rosacea).

MaxCyte is a clinical stage drug development company. MaxCyte has developed a novel and proprietary platform for next-generation CARs and a CAR for solid tumors. The company has entered the clinic with its first cell therapy, MCY-M11 for ovarian cancer and peritoneal mesothelioma.

Mercator has near term commercial viability, a successful Phase II study in delivering a limus drug, in peripheral arterial disease where less efficient delivery technologies, drug coated balloons, have experienced rapid market adoption. These technologies have the potential for ongoing collaboration and clinical development with Biotech startups and big Pharma.

Mesoblast has one of the strongest pipelines in the cellular medicine space with clinical programs in SR-aGvHD, Class IIb/III HF, End Stage (Class IV) HF using LVAD and Chronic Lower Back Pain. Mesoblast has multiple milestones over the coming 12-18 months.

Data from Phase I and pre-clinical development shows the Company's lead compound, MGB-BP-3, is superior to vancomycin and prevents sporulation, the major cause of recurrence of disease. MGB-BP-3 is rapidly bactericidal even against hypervirulent strain NAP1/027. FDA have agreed a rapid development plan.

Based on off-study reports of complete tumour responses, MiNA is currently conducting a Phase 1b in sequence/combination with standard-of-care Sorafenib and planning for a registrational Phase 2 study to start next year. MTL-CEBPA is understood to disrupt the tumour-immune-microenvironment, which can overcome tumour resistance to several agents including checkpoint inhibitors.

MIP Diagnostics is exploiting a platform technology to provide nanoMIPs, or "plastic antibodies" for a wide range of applications. Having secured revenues from its custom service offering they are now developing assets for partnering/licencing. They are seeking further investment to enable rapid expansion to meet market needs.

Mitochon is in a unique position of having an open IND and significant compelling pre-clinical data that has demonstrated efficacy in a host of neurodegenerative diseases with unmet need (Huntington’s, Parkinson's, etc). They have an experienced management team and expect future investments to return greater than 10x in 3-5 years.

Exclusive access to novel, proprietary technology to characterize the complement to genomics. Prototype instruments built and sample analysis collaborations with pharma customers to address blindspots in biologics characterization in progress. Minutes vs. hours throughput and unprecedented analytical power provide most comprehensive multi-omics database for data monetization opportunity beyond instrument sales.

Motus GI is a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy. The Company’s flagship product is the Pure-Vu® System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure.

LBL is an IND-enabling stage company, its leading project LBL-007, a fully human anti-LAG-3 antibody will file IND and enter clinical trials in early 2019. 2 other programs, one single checkpoint antibody and one bi-specific checkpoint antibody will enter CMC development and non-clinical studies in 2019 as well.

This company is developing, and has patent protected, a new class of medicines, with novel mechanisms of action and activity against KRAS mutant tumors, which represent one of the key unmet needs in oncology. This new class of medicines has many potential uses in oncology and beyond.

NanoViricides is an advanced preclinical stage company readying to move into the clinical phase of drug development with its innovative technology platform. Proof of concept preclinical data have been obtained on the company's candidate drug products. The company's Connecticut facility is equipped for Good Manufacturing Practice (GMP)-compatible manufacture of nanoviricides.

The company is seeking partners with existing portfolios that would benefit from access to its unique datasets and analytic capabilities. Nashville Biosciences is also developing a portfolio of asset concepts based on proprietary internal R&D and plan to raise $5M in 2019.

Navigen has developed a proprietary platform for the discovery of D-peptide therapeutics. They are developing their own D-peptide assets, one of which is approximately one year from the clinic and are pursuing research collaborations with pharma partners to develop D-peptides for their targets of interest.